cangrelor
Sign in to saveCangrelor, sold under the brand name Kengreal among others, is a P2Y12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation.
Key facts
- Drug.image
- Cangrelor structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 300
- Drug.tradename
- Kengreal, Kengrexal, others
- Drug.DailyMedID
- Cangrelor
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- B01
- Drug.ATC_suffix
- AC25
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- 100% (IV)
- Drug.protein_bound
- ~97–98%.
- Drug.metabolism
- Rapid deactivation in the circulation (independent of CYP system)
- Drug.elimination_half life
- ~3–6 minutes
- Drug.excretion
- Kidney (58%), Bile duct (35%)
- Drug.index2_label
- as salt
- Drug.IUPHAR_ligand
- 1776
via Wikipedia infobox
Article
7 sectionsContents
- Medical use
- Adverse effects
- Pharmacology
- Chemistry
- Synthesis
- Research
- References
Cangrelor, sold under the brand name Kengreal among others, is a P2Y12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation.
It is authorized as a generic medication.